PROPOFOL
Metabolic Disease
Baskent UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Metabolic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tirzepatide Washington University School of Medicine | Phase 4 | BBB |
MIDAZOLAM Baskent University | Phase 4 | BB |
GLUCOSE, ANHYDROUS University Hospital Schleswig-Holstein | Phase 4 | BB |
Terazosin I.R.C.C.S. Fondazione Santa Lucia | Phase 4 | BB |
Orlistat Novo Nordisk A/S | Phase 2 | B |
View all 32 →
Same molecule, other indications
PROPOFOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →